MetaCap

GRI Bio (GRI) vs Traws Pharma (TRAW)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Traws Pharma is the larger company by market cap ($2.7 million vs $2.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GRI-39.46%TRAW-63.47%
+5%-31%-67%
Oct 7, 20261 yearNov 20, 2026
GRI-35.63%TRAW-60.69%
+11%-26%-64%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GRI versus TRAW key metrics
MetricGRITRAW
Share price$1.12$0.175
Market cap$2.45M$2.69M
1-day change0.00%-23.91%
P/E ratio (TTM)0.05—
EPS (TTM)$20.57$-1.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.79M
Revenue growth (YoY)—+1134.51%
Net income (latest FY)$-11.96M$9.17M
Operating margin—-640.68%
Net margin—328.67%
52-week high$64.12$3.23
52-week low$1.09$0.1698
Distance from 52-week high-98.25%-94.58%
Analyst consensusnonenone
Avg. price target upside+1551.79%+471.43%
Average volume218.31K610.04K
Shares outstanding2.19M15.37M
Employees34
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About GRI Bio

GRI stock →

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

About Traws Pharma

TRAW stock →

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

GRI vs TRAW FAQ

Which is bigger, GRI Bio or Traws Pharma?

Traws Pharma (TRAW) is larger, with a market capitalization of $2.69M compared with $2.45M for GRI Bio (GRI).

Are GRI Bio and Traws Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons